Join to view full profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Dr. Siefker-Radtke is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1999 - 2002
Tufts Medical CenterResidency, Internal Medicine, 1996 - 1999
Johns Hopkins University School of MedicineClass of 1996
Certifications & Licensure
FL State Medical License 2021 - Present
TX State Medical License 2001 - 2026
OK State Medical License 2020 - 2021
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2013-2015
Clinical Trials
- SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment
- Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone Start of enrollment: 2003 Mar 20
- Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant Start of enrollment: 2003 Apr 23
Publications & Presentations
PubMed
- Incidence and outcomes of FGFR inhibitor-associated retinopathy of patients treated with oral erdafitinib across the clinical trial program.Anne O'Hagan, Arlene Siefker-Radtke, Yohann Loriot, Kris Deprince, Lauren Crow
The Oncologist. 2026-06-06 - Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group.Shilpa Gupta, Roger Li, Patrick J Hensley, Siamak Daneshmand, Bishoy M Faltas
European Urology. 2026-06-01 - Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma.Kai Yu, Rebecca S Tidwell, Tharakeswara K Bathala, Rahul A Sheth, Menuka Karki
Clinical Cancer Research. 2026-05-15
Lectures
- Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update from CheckMate 275.2019 ASCO Annual Meeting - 6/1/2019
- FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary anal...2019 ASCO Annual Meeting - 6/1/2019
- Tailoring of Chemotherapy to Fit Patients With Metastatic Urothelial Cancer2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Press Mentions
What’s the Right Dose and Duration for EV-Pembro in Bladder Cancer?June 24th, 2025- NCCN Clinical Practice Guidelines in Oncology: 2023 UpdatesMay 19th, 2023
- Can Frequent UTIs Be a Sign of Bladder Cancer?March 9th, 2023
Grant Support
- Lineage plasticity sensitizes FGFR3-mutant bladder cancer to FGFR inhibitorsUNIVERSITY OF TX MD ANDERSON CAN CTR2026–2031
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
